What are the barriers faced by patients using insulin? A qualitative study of Malaysian health care professionals’ views by Khoo, E.M. et al.
© 2013 Lee et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Patient Preference and Adherence 2013:7 103–109
Patient Preference and Adherence
What are the barriers faced by patients using 
insulin? A qualitative study of Malaysian health 
care professionals’ views
Yew Kong Lee1
Chirk Jenn Ng1
Ping Yein Lee2
Ee Ming Khoo1
Khatijah Lim Abdullah3
Wah Yun Low4
Azah Abdul Samad5
Wei Seng Chen6
1Department of Primary Care 
Medicine, Faculty of Medicine, 
University of Malaya, Kuala Lumpur, 
Malaysia; 2Department of Family 
Medicine, Universiti Putra Malaysia, 
Serdang, Selangor, Malaysia; 
3Department of Nursing Sciences, 
Faculty of Medicine, University of 
Malaya, Kuala Lumpur, Malaysia; 
4Faculty of Medicine Dean’s Office, 
University of Malaya, Kuala Lumpur, 
Malaysia; 5Klinik Kesihatan Pantai, 
Kuala Lumpur, Malaysia; 6Klinik Alam 
Medic, Puchong, Selangor, Malaysia
Correspondence: Yew Kong Lee 
Department of Primary Care Medicine, 
Faculty of Medicine, University of Malaya, 
50603 Kuala Lumpur, Malaysia 
Tel +60 3 7949 2306 
Fax +60 3 7957 7941 
Email leeyk@um.edu.my
Background: Patients with type 2 diabetes often require insulin as the disease progresses. 
However, health care professionals frequently encounter challenges when managing patients 
who require insulin therapy. Understanding how health care professionals perceive the barriers 
faced by patients on insulin will facilitate care and treatment strategies.
Objective: This study explores the views of Malaysian health care professionals on the barriers 
faced by patients using insulin.
Methods: Semi-structured qualitative interviews and focus group discussions were conducted 
with health care professionals involved in diabetes care using insulin. Forty-one health care 
professionals participated in the study, consisting of primary care doctors (n = 20), family 
medicine specialists (n = 10), government policymakers (n = 5), diabetes educators (n = 3), 
endocrinologists (n = 2), and one pharmacist. We used a topic guide to facilitate the interviews, 
which were audio-recorded, transcribed verbatim, and analyzed using a thematic approach.
Results: Five themes were identified as barriers: side effects, patient education, negative per-
ceptions, blood glucose monitoring, and patient adherence to treatment and follow-up. Patients 
perceive that insulin therapy causes numerous negative side effects. There is a lack of patient 
education on proper glucose monitoring and how to optimize insulin therapy. Cost of treatment 
and patient ignorance are highlighted when discussing patient self-monitoring of blood glucose. 
Finally, health care professionals identified a lack of a follow-up system, especially for patients 
who do not keep to regular appointments.
Conclusion: This study identifies five substantial barriers to optimizing insulin therapy. 
Health care professionals who successfully identify and address these issues will empower 
patients to achieve effective self-management. System barriers require government agency in 
establishing insulin follow-up programs, multidisciplinary diabetes care teams, and subsidies 
for glucometers and test strips.
Keywords: primary care, focus groups, noncommunicable disease, diabetes, insulin, 
qualitative study
Introduction
Type 2 diabetes affects 366 million people worldwide. This figure is expected to rise to 
552 million by 2030.1 Insulin remains one of the most effective methods for achieving 
glycemic control in patients with type 2 diabetes, either alone or in combination with 
anti-diabetic oral medications.2 Despite this, patients are generally reluctant to start 
insulin therapy.3,4 Barriers to starting insulin are well documented in the literature3,5–7 
and initial reluctance is viewed as the major hurdle in patients with type 2 diabetes.
However, barriers at initiation are only one part of the problem as patients continue 
to encounter barriers after insulin initiation,7 and up to a third of patients admit to 
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non-adherence to insulin regimes.8 Giving more precise 
recommendations does not improve adherence rates9 as 
barriers to adherence are related to patient perception and 
acceptance of insulin therapy.9,10 Patients using insulin need 
to be continuously educated and empowered to self-manage 
their insulin regiment.11 However, this can only be achieved 
if health care professionals (HCPs) are aware of the problems 
faced by patients.
Malaysia has the highest prevalence rate of type 2 
diabetes (11.7%) in the Western Pacific region, and this 
figure is projected to rise to 13.3% by 2030.12 The majority 
of patients in Malaysia have poor glycemic control; only 
about 20% have HbA
1c
 levels of less than 7%.13–15 This leads 
to an increase in micro- and macrovascular complications, 
which impose a heavy burden on the country’s already 
stretched health care system,16 in which cardiovascular 
disease accounts for the highest number of hospital 
deaths.17
Little research has been done on Malaysian HCPs’ views 
of patient barriers to insulin use. Understanding this will 
create strategies to help HCPs care for patients on insulin 
therapy. This study therefore aims to explore HCPs’ views 
on the barriers faced by patients using insulin. It is part of 
a larger 3-year study to develop an intervention to assist in 
shared decision-making in insulin therapy.
Methods
Design
This was a qualitative study using semi-structured individual 
interviews and focus groups to identify and explore the views 
of HCPs on the barriers faced by patients using insulin. The 
in-depth interviews, focus group discussions, and field notes 
provided the basis for data analysis.
Setting
Malaysia has a dual-sector health system comprising 
government-subsidized public health facilities and private 
fee-for-service clinics and hospitals. The majority of patients 
with type 2 diabetes are treated in public health facilities 
as the cost is lower. In public primary care settings, family 
medicine specialists and medical officers initiate insulin 
therapy as only doctors are allowed to do so in Malaysia. 
Diabetes nurse educators provide patient education and 
follow-up. In the private sector, management of diabetes care 
is dependent on the doctor, as most clinics are solo practices 
that do not have support from a diabetes care team or nurse 
educators. Such disparities in care give rise to different 
barriers faced by private and public patients.
The sample comprised HCPs who provide diabetes care in 
the three health care settings in Malaysia: public health clinics 
(both urban and semi-rural); public university-based primary 
care clinics and hospitals; and private general practice clinics 
and hospitals. Key government policymakers who plan 
national diabetes strategies were also interviewed.
Participants, recruitment, sampling
Primary and secondary care HCPs who provide diabetes care, 
including insulin therapy, were recruited using purposive sam-
pling and snowball methods. For recruiting focus groups, we 
selected participants based on their specialties and their health 
care system. This was to ensure homogeneity and to capital-
ize on shared experiences.18 Participants of the focus groups 
comprised two groups of general practitioners working in the 
private setting (n = 11), trained primary care doctors (family 
medicine specialists) working in public health clinics (n = 8), 
and untrained primary care doctors (medical officers) from a 
university-based primary care clinic (n = 8). In-depth interviews 
were conducted for government policymakers and for HCPs 
who were unable to attend a focus group session due to other 
commitments. Sample size was determined by data saturation 
and interviews were stopped when a consensus was reached 
among three researchers that the data categories were established 
and that any new data would fit into categories already devised. 
We also interviewed patients with type 2 diabetes; these study 
findings will be reported separately.
Data collection
An interview topic guide was developed based on a literature 
review, clinical knowledge, and research experience. 
Participants were asked about diabetes management in 
general and barriers to insulin use encountered in their clinical 
experience, including barriers faced by patients. The same 
guide was used for both individual and focus group discussions. 
The interviews and focus group discussions were carried out 
by one of the four researchers, who are trained to conduct 
qualitative interviews. Care was taken to avoid interviews 
being conducted by close acquaintances of the participants 
to prevent potential response bias. A research assistant took 
detailed notes and observations of nonverbal cues during the 
interviews, which were used as field notes. From October 2010 
to May 2011, we conducted 14 individual interviews, each 
lasting 30 to 40 minutes, and held four focus group discussions, 
each of which lasted for 1 hour. All interviews and focus group 
discussions were audiotaped and transcribed verbatim. Each 
transcript was checked for accuracy by another transcriber and 
used as data for analysis.
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Data analysis
The researchers first scrutinized the data before applying a 
thematic analysis approach to identify the main themes. To 
maximize the validity of the analytical interpretations, three 
researchers independently coded two transcripts to determine 
the coding frame. This framework was then used to code two 
other transcripts individually. Any coding discrepancies were 
resolved by discussion until a consensus was reached. The 
final list of nodes was used as a framework for coding the 
rest of the transcripts. New nodes emerging during coding 
were added to the list upon consultation with other research-
ers. Nvivo9 software (QSR International Pty Ltd, Doncaster, 
Victoria, Australia) was used for data analysis. The list of 
nodes was regrouped into larger categories as themes emerged 
from the data. This systematic approach to the analysis con-
tributes to the establishment of an “audit trail” from the 
transcripts of raw data through to the final interpretation.
Researchers analyzing the data were family medicine 
specialists and psychologists. They reflected and debated on the 
potential biases to improve the credibility of the analysis.
Ethics approval
This study received ethics approval from the Medical 
Research and Ethics Committee, Ministry of Health, 
Malaysia (reference: NMRR-10-1233-7299).
Results
Forty-one HCPs involved in the care of patients using insulin 
participated in the study (see Table 1 for demographic 
characteristics). A descriptive model emerged from the 
thematic analysis, where HCPs identified five types of 
challenges faced by patients: issues related to side effects, 
patient education, negative perceptions, self-monitoring of 
blood glucose, and follow-up of patients. (Illustrative quotes 
are reported verbatim.)
Side effects of insulin
HCPs view side effects experienced by insulin users, such 
as weight gain and hypoglycemia, as a challenge. Severe 
episodes of hypoglycemia are traumatic enough to stop 
patients from using insulin altogether:
If you highlight the weight gain, it’s gonna be a big barrier to 
it. So, um … the subject of weight gain usually comes about 
once they’re on insulin already. Because unavoidably, you 
mention weight every visit and then you see the weight going 
up every visit, the more the insulin, the more the weight, then 
you have to tell them … very quickly, you say “side effects 
of insulin.” [Endocrinologist, public tertiary care hospital]
I have a friend who is an O and G [obstetrics and gynecology] 
consultant; he was on insulin. What happened was I think 
he skipped his breakfast, so he went into hypoglycemic 
coma while he was driving. So they stopped the car at the 
traffic lights … so lucky you know, the passers-by take him 
to hospital. After that, until now, he refuses to take insulin. 
[General practitioner, private general practice]
Patient education
HCPs felt that patients do not receive enough information 
on adjusting the insulin dose to optimize insulin regimes. In 
addition, patient education is time consuming:
So … the most common thing, what happen is, people start 
insulin, but after that, they don’t optimize and specify the 
regime. The patient who started just on one regime for, like, 
many years and nobody have actually taught the patient 
how to do the self-titration of the insulin too … and that 
requires more time because you really have to sit down, tell 
the patient, “Ok, you are now in this regime, this insulin,” 
erm … “action is for this long.” [Family medicine specialist, 
public health clinic]
Negative perceptions about insulin
HCPs identified negative perceptions that caused patients to 
discontinue insulin usage. Patients believe that they only need 
to use insulin when their glucose levels are high, or that they 
could stop using insulin when they feel better:
Table 1 Demographic profile of participants 
Characteristics Number
(n = 41)
% Mean ± SD 
(range), years
Age 46.6 ± 9.8 
(30–66)
Sex
 Female 31 75.6
 Male 10 24.4
Ethnicity
 Malays 15 36.6
 Chinese 10 24.4
 indians 13 31.7
 Other 3 7.3
Professional background
 Primary care doctor 20 48.8
 Family medicine specialist 10 24.4
 government policy maker 5 12.2
 Diabetes nurse educators 3 7.3
 Endocrinologists 2 4.9
 Pharmacist 1 2.4
health care sector
 Public 26 63.4
 Private 15 36.6
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I’ve seen so many patients who have been given insulin from 
the hospital; they will come and say, “Doctor, this is given 
but I’m not using it.” Only sometimes they will monitor, 
when it’s high, 25–30, then they will inject themselves. 
[General practitioner, private general practice]
R1: Maybe they [patients] will continue [using insulin] for 
a while, they will get better, they said, “No, I don’t want 
injection anymore.”
R2: They said “I am better, so I can stop now.” [General 
practitioners, private general practice]
Some patients were reluctant to follow the recommended 
treatment regime as it was seen as conflicting with their diet 
and lifestyle:
Maybe [we] can just choose, we [HCPs] cannot give three 
pre-mixed, you know … so it depends how their [patients’] 
lifestyle. It depends on their work also … how’s their work-
ing and meal times. Their mealtimes also … they will tell 
us. Because when we negotiate, you know, some, they said 
okay, after negotiating, then they’re okay. Then they try to 
follow. But some they said cannot … they still want to; 
they want us to follow them … to follow their meal times. 
[Family medicine specialist, public health clinic]
Blood glucose monitoring
Cost was a deterrent to purchasing a glucometer for 
self-monitoring of blood glucose (SMBG), especially for 
patients from less affluent backgrounds:
I think quite many [patients] don’t have glucometer … I 
don’t have the figure, but I think so, because, like I told 
you … the majority that comes here is from low and middle 
class. Sometimes, maybe they give priority to other things. 
Means … maybe, actually it’s not because they don’t have 
money … but they maybe used the money for other things 
first. [Family medicine specialist, public health clinic]
It was difficult for patients to carry out SMBG because 
glucometers were not provided, even though insulin and pens 
were subsidized in the public setting. In addition, SMBG kits 
were not available at certain locations:
How come when we [public health clinics] give all 
[insulin and pens], we provide everything free, but the 
glucometer is not given, test strips are not given, and how 
are they [patients] monitoring the blood glucose? [General 
practitioner, private general practice]
But you know, when I go and practice in Kuantan and 
Terengganu, I don’t have this [a subsidy scheme for SMBG 
kits]. You know, I’m lost! And the patients are so bad. 
You can just imagine how terribly … these are patients being 
held up in … in … in state hospitals, in specialist clinics. 
And they’ve been on insulin for years and they don’t moni-
tor their sugar and to start them on is difficult because the 
resource center has no way that they can get a glucometer, 
you know. [Endocrinologist, public tertiary hospital]
Other barriers to SMBG are a lack of awareness on the 
importance of SMBG and the fear of finger pricking:
Those who can afford also don’t see that it’s important 
to invest on the glucometer … And then after that is the 
problem of having the meter, but they’re not doing. When 
we talk about meter and everything, you have to talk about 
fear of pricking. That’s another barrier. [Family medicine 
specialist, public health clinic]
Lack of continuity of care
There is a lack of continuity of care in both public and private 
settings for patients on insulin therapy:
Then the trouble that I’ve found is that when they’re 
[patients] on [insulin], I don’t know what’s happening. In 
fact, sometimes they don’t want to see me. They just come 
and collect medicine. Then I say, “Hey, haven’t seen you 
for a long time, what happened?” [General practitioner, 
private general practice]
A lot of patients are referred at diagnosis [to tertiary care], 
at the initiation of insulin, and that’s it. So, there’s nothing 
in between, you know. And you know … you [patients] can’t 
remember everything that people tell in the beginning. So, 
probably these insulin users should have a regular follow-
up, just like a follow-up with your doctor. [Endocrinologist, 
public tertiary care hospital]
System change
The government has changed suppliers of insulin pens, 
leading to confusion among patients as they need to learn 
how to use a different type of insulin pen:
So [Company A], got [Pen A]. Then they [the government] 
give the tender to [Company B], we have got no choice just 
to switch everybody on [Company B] pen. So now, we have 
both. So, I suppose it’s up to doctor. What is most important 
is actually that if the patient already have one, you start them 
on bedtime insulin – they already have one pen. So you try 
to give similar pen, so that they don’t get confused. Yeah … 
they don’t have to learn two different type of pen. [Family 
medicine specialist, public health clinic]
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Discussion
This qualitative study helps to shed light on HCPs’ views of 
barriers faced by patients on insulin therapy, which is an area 
that has been prioritized under recent policy initiatives by the 
Malaysian Ministry of Health (MOH) for patient adherence 
in non-communicable diseases.19 The government focus is on 
empowering patients in self-management through inter-personal 
health education programs run by trained diabetes educators 
and specifically for diabetes, making available subsidized 
glucostrips for SMBG.19 Our study shows that HCPs view the 
attainment of these targets differently. HCPs highlighted the 
lack of patient education activities and continuity of care. In 
addition, SMBG subsidies are still unavailable.
Main findings and comparisons  
with other studies
HCPs generally have poor expectations of patient adherence 
to insulin therapy. Up to 92.3% of doctors believe that patients 
would not comply with insulin treatment20 and a multinational 
survey reported that 72.5% of their patients did not comply 
with insulin regimes.8 Therefore, as documented in our 
results, it is expected that Malaysian HCPs would report a 
variety of barriers to insulin use. The results of our study are 
discussed in comparison with other studies.
HCPs view patients’ negative experiences of insulin side 
effects, especially hypoglycemia, as a major barrier. This is 
consistent with a recent report that fear of hypoglycemia 
(FoH) is still a widespread phenomenon, with a significant 
negative impact on diabetes management, metabolic control, 
and subsequent health outcomes.21 Besides that, although the 
use of newer insulin analogs reduces the risk of hypoglycemic 
episodes,22,23 cost is a concern. It is important to educate 
patients on observing regular meals to avoid hypoglycemia 
and to conduct blood glucose awareness training.24 Cognitive 
behavior therapy25 can help reduce patient fears and anxiety 
associated with fear of hypoglycemia.
Studies elsewhere have also reported that patient 
misperceptions about increased insulin dosage and disease 
deterioration are barriers for insulin users.26,27 Strategies 
to overcome these include structured patient education 
training and follow-up programs. These have been shown to 
significantly improve the management of diabetes28 as well 
as reduce diabetes-related distress.29 However, implementing 
insulin follow-up and education for patients requires sufficient 
staff resources. In Malaysia, this translates into training more 
diabetes nurse educators as there is a severe shortage.
HCPs perceive that patient follow-up is inconsistent or 
non-existent in some settings. Developing an effective system 
of follow-up would require the integration of care and follow-up 
between public and private sectors and the involvement of non-
government agencies.30 Possible strategies include allowing 
referral of private patients to public sector insulin initiation 
and follow-up programs, as well as introducing shared care 
between the two sectors to reduce the disproportionately heavy 
workload faced by the public sector.30
The cost of SMBG kits was highlighted as a barrier. 
Thus, it is encouraging that providing financial support for 
SMBG has been identified as a key public policy initiative 
for diabetes.19 In Malaysia, the cost of insulin and pens are 
subsidized in public settings, but SMBG kits and test strips 
are out-of-pocket expenses for patients. However, the proposed 
subsidy for glucostrips has yet to be implemented in practice. 
Currently, patients receive financial assistance in the form of 
discounted glucometers from companies; however, patients are 
still required to pay out-of-pocket for glucostrips. Feedback 
from private sector HCPs suggests that access to public sector 
support for SMBG should be extended to patients in private 
health care as cost is also a concern for them. Another challenge 
related to public policy and practice is the awarding of contracts 
to companies to supply insulin and insulin pens to public health 
clinics as the majority of patients with chronic conditions are 
treated in public facilities.31,32 The change in insulin pens can 
cause confusion among patients who need to learn how to use 
the new pen. Options should be made available to allow patients 
to continue using the pen they are familiar with.
Strengths and limitations
This study’s strength is that the sample comprises a 
broad spectrum of settings and professionals involved in 
diabetes care. Thus, researchers are able to gain an in-depth 
understanding of the challenges to insulin use from HCPs 
from different settings. As an exploratory study, the results 
indicate that HCPs are aware of the problems faced by patients. 
More research is needed to study the prevalence and severity 
of these barriers. Such information would ensure that barriers 
to patient adherence to insulin can be addressed before, during, 
and even after insulin initiation, such as in the case of patients 
who discontinue use due to anxiety and require counseling.
One limitation of this study is that only HCPs’ views 
on patient barriers were explored. Patient perspectives will 
be explored as part of a larger study and compared with 
challenges identified by HCPs.
Conclusion
This study discusses barriers faced by patients using insulin 
after initiation. Issues such as fears, misperceptions, and side 
effects can be substantial barriers and HCPs who successfully 
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identify and address these issues can empower patients to 
achieve effective self-management. Overcoming system 
barriers requires government initiative to establish insulin 
follow-up programs, multidisciplinary diabetes care teams, 
and subsidies for glucometers and test strips.
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